We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

35 hedge funds and large institutions have $5.47M invested in Titan Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

13% less funds holding

Funds holding: 40 → 35 (-5)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

50% less capital invested

Capital invested by funds: $10.9M → $5.47M (-$5.41M)

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
5
Reduced
8
Closed
16
Calls
$190K
Puts
–
Net Calls
+$190K
Net Calls Change
-$543K

Top Buyers

Rank Fund Capital Flow
1
MERSOM
Municipal Employees' Retirement System of Michigan
Michigan
+$782K
2
Millennium Management
Millennium Management
New York
+$595K
3
WPA
Winning Points Advisors
Florida
+$381K
4
ECM
Element Capital Management
New York
+$214K
5
PP
Paloma Partners
Connecticut
+$186K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.91M
2
Northern Trust
Northern Trust
Illinois
-$409K
3
SO
STRS Ohio
Ohio
-$354K
4
TCIM
TIAA CREF Investment Management
New York
-$180K
5
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$128K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Wealthspire Advisors (Maryland)
Maryland
$22K – – –
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$17K – – –
Wells Fargo
28
Wells Fargo
California
$13K – – –
DADC
29
D.A. Davidson & Co
Montana
$9K -$18.6K -2 -67%
WIM
30
Westside Investment Management
California
$5.85K – – –
BCM
31
Blume Capital Management
California
$5K – – –
MAM
32
Meeder Asset Management
Ohio
$4K – – –
UBS Group
33
UBS Group
Switzerland
$4K +$9.3K +1 New
AIM
34
Acrospire Investment Management
Illinois
$3K -$55.8K -6 Closed
AIM
35
Arcadia Investment Management
Michigan
$3K – – –
AG
36
Advisor Group
Arizona
$2K – – –
KF
37
Krilogy Financial
Missouri
$2K – – –
TDC
38
Thompson Davis & Co
Virginia
$2K – – –
DOA
39
D'Orazio & Associates
Virginia
$1K – – –
Simplex Trading
40
Simplex Trading
Illinois
$1K – – –
GS
41
Gagnon Securities
New York
$67 +$93K +10 New
IWM
42
IHT Wealth Management
Illinois
$43 – – –
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$4 – – –
SO
44
STRS Ohio
Ohio
– -$354K -30 Closed
TCIM
45
TIAA CREF Investment Management
New York
– -$180K -15 Closed
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
– -$128K -11 Closed
TA
47
Teachers Advisors
New York
– -$120K -10 Closed
AllianceBernstein
48
AllianceBernstein
Tennessee
– -$102K -9 Closed
Charles Schwab
49
Charles Schwab
California
– -$100K -8 Closed
RHBC
50
R.H. Bluestein & Co
Michigan
– -$73K -6 Closed
1
2
3

TTNP Hedge Fund Activity: Q2 2017 in Review

35 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2017, worth a combined $5.47M — down 50% from $10.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of TTNP and 11 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Municipal Employees' Retirement System of Michigan, opening a new position worth an estimated $782K. The largest seller was BlackRock, cutting an estimated $1.91M.

  • 35 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2017, down from 40 in Q1 2017.
  • Funds reported $5.47M of Titan Pharmaceuticals stock for Q2 2017, down 50% quarter-over-quarter.
  • 11 funds opened new Titan Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of -5 holders.
  • The largest Titan Pharmaceuticals buyer in Q2 2017 was Municipal Employees' Retirement System of Michigan, an estimated $782K added.
  • The largest Titan Pharmaceuticals seller in Q2 2017 was BlackRock, an estimated $1.91M sold.

Based on aggregated 13F filings for Q2 2017.